(MNMD) – Press Releases
-
MindMed to Present at Upcoming April Medical Conferences
-
MindMed Announces Voluntary Delisting from Cboe Canada
-
MindMed to Participate in the Leerink Partners 2024 Global Biopharma Conference
-
Numinus Wellness Congratulates MindMed on Positive Results from Phase 2B Clinical Trials of MM120 for Generalized Anxiety Disorder
-
Mind Medicine (MindMed) Inc. Announces Pricing of Underwritten Offering of Common Shares and Concurrent Private Placement
-
MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder
-
MindMed to Host Conference Call and Webcast to Discuss Data Update for MM120
-
MindMed Reports 2023 Financial Results and Business Updates
-
MindMed to Host Conference Call and Webcast to Discuss 2023 Financial Results and Provide Business Update
-
MindMed to Participate in the 34th Annual Oppenheimer Healthcare Life Sciences Conference
-
MindMed Announces Business Update and Anticipated Milestones for 2024
-
MindMed Announces Positive Topline Results from Phase 2b Trial of MM-120 in Generalized Anxiety Disorder
-
MindMed Reports Third Quarter 2023 Financial Results and Business Highlights
-
MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2023 Financial Results and Provide Business Update
-
MindMed Completes Enrollment of Phase 2a Trial of MM-120 in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD)
-
MindMed to Present Data on the Preclinical Activity of MM-402 at the 36th Annual European College of Neuropsychopharmacology (ECNP) Congress
-
MindMed to Participate in the TD Cowen 3rd Annual Novel Mechanisms in Neuropsychiatry Summit
-
MindMed Completes Enrollment of Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD)
-
MindMed to Participate at September Investor Conferences
-
MindMed Secures $50.0 Million Credit Facility with K2 HealthVentures
-
MindMed Reports Second Quarter 2023 Financial Results and Business Highlights
-
MindMed Announces Exclusive License Agreement With Catalent for Its Patented Zydis® Fast-Dissolve Technology for Use with MM-120
-
MindMed to Host Conference Call and Webcast to Discuss Second Quarter 2023 Financial Results and Provide Business Update
-
FCM Received Significant Support from Shareholders, Disappointed that “Passive” Investors Saw Fit to Give Incumbent Directors Another Chance to Disappoint
-
MindMed to Participate in the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference
-
MindMed Announces Election of All Six Company Nominees at Annual Meeting
-
MindMed Provides Overview of Clinical Progress and Corporate Updates at Investor Day
-
FCM Denounces MindMed’s Manipulation of Corporate Machinery to Protect Incumbent Board of Directors
-
MindMed Adjourns Annual General Meeting of Shareholders
-
FCM Calls for Socially Responsible Investors to Vote for Change at MindMed
-
MindMed Urges Shareholders to Vote TODAY for Company Nominees Ahead of June 13th Deadline
-
Leading Proxy Advisory Firm Glass Lewis Recommends MindMed Shareholders Vote FOR All Six Company Nominees
-
FCM Plans for MM-120 (LSD) FDA Approval in 2026 And Extends Share Lockup Until June 15, 2026
-
MindMed to Host Investor Day June 2023
-
Leading Proxy Advisory Firm ISS Recommends MindMed Shareholders Vote FOR All Six Company Nominees
-
Cedar Clinical Research, by Numinus, the top enrolling clinical research site for MindMed's Phase 2B study evaluating MM-120
-
ISS Appears to Rely on MindMed's False and Misleading Statements to Justify the Company's Abysmal Performance; Seemingly Ignores MindMed's Apparent Disregard of Patient Safety
-
FCM Predicts Psychedelic Revolution In 2024: Urges Shareholders to Position MindMed for Success with a Reconstituted Board
-
MindMed to Participate at Upcoming Investor Conferences
-
FCM Pledges to Lock Up its MindMed Shares Until June 2025 to Demonstrate its Alignment with Fellow Shareholders and Confidence in its Plan to Restore MindMed
-
FCM Concerned MindMed’s Mismanagement Threatens Mental Health for Millions
-
MindMed Releases Investor Presentation Highlighting How the Company is Unlocking the Power of Psychedelics for Patients and Shareholders
-
MindMed Publishes Report by Leading FDA Experts Validating MindMed’s MM-120 Drug Development Strategy
-
MindMed to Present Data on the Preclinical Activity of MM-402 at the American Society of Clinical Psychopharmacology (ASCP) 2023 Annual Meeting
-
MindMed Announces Enrollment Milestone in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD)
-
FCM Director Nominees Will Put MindMed Drug Development Process Back on Track
-
FCM Releases Letter to Fellow MindMed Shareholders Highlighting Board and Management’s Track Record of Shareholder Value Destruction
-
MindMed Reports First Quarter 2023 Financial Results and Business Highlights
-
MindMed Sends Letter to Shareholders Highlighting Company’s Positive Momentum and Value-Enhancing Strategy
-
MindMed to Host Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Business Update
Back to MNMD Stock Lookup
